The identification of <i>TP53</i> and <i>STAG2</i> as prognostic markers highlights the potential value of broader genomic profiling for biologically informed risk stratification in urothelial bladder cancer. The gene discussed is STAG2; the disease is bladder transitional cell carcinoma.